Conference to Discuss Antibiotic-Resistant Bacteria Responsible for Sarcoidosis and Other Autoimmune Diseases

Share Article

Having demonstrated that antibiotic-resistant bacteria are the cause of sarcoidosis, the Autoimmunity Research Foundation is bringing its new-found knowledge to bear on other autoimmune diseases, AIDS and cancers. Alan Cantwell Jr., M.D. will headline the foundation’s conference June 17-18, 2006, discussing the role of cell-wall-deficient bacteria in AIDS and cancer.

Thousand Oaks, CA (PRWEB)May 16, 2006

Having demonstrated that antibiotic-resistant bacteria are the cause of sarcoidosis, the Autoimmunity Research Foundation is bringing its new-found knowledge to bear on other autoimmune diseases, AIDS and cancers. Alan Cantwell Jr., M.D. will headline the foundation’s conference June 17-18, 2006, discussing the role of cell-wall-deficient bacteria in AIDS and cancer.

In 1994, Dr. Cantwell’s book on AIDS, "Queer Blood," won the Benjamin Franklin Book Award for literary excellence. There is probably no other physician whose cancer and AIDS publications are so well known -- and so controversial. Dr. Cantwell’s work supports the concept that several ailments considered to be “autoimmune disease” may in reality be chronic infections not easily detected by standard laboratory testing techniques.

Trevor Marshall, Ph.D., will explain how hidden bacteria cause disease as well as how to select antibiotics capable of treating chronic diseases including sarcoidosis, rheumatoid arthritis, thyroiditis, chronic fatigue syndrome and fibromyalgia.

Dr. Marshall’s recent papers have shown how modern molecular genomics have produced a more complete understanding of the way these diseases develop and how they can be effectively treated. His conference presentation will address the issue of antibiotic resistance as well as molecular genomics in the pathogenesis of chronic immune diseases.

The Autoimmunity Research Foundation is a non-profit organization. The foundation successfully sponsored an application to the FDA resulting in the designation of orphan-drug status for the common antibiotic minocycline for use in treating sarcoidosis. “FDA designation of orphan drug status for minocycline is a huge breakthrough, but it’s only one part of our successful intervention,” said Dr. Marshall. “This treatment is based on a detailed knowledge of the bacterial pathogenesis and is aimed at treating the cause of disease rather than simply controlling symptoms.”

The conference “Recovering from Chronic Disease,” sponsored by the Autoimmunity Research Foundation, is designed for patients as well as medical professionals. It will be held June 17-18, 2006 at the Los Angeles Airport Hilton. The conference fee is $95 for registration before May 22 and $115 thereafter. Registration may be completed online at the foundation’s website: Online Registration LAX. Detailed information on registration, speakers and times is online at: June 17-18 LAX Conference Brochure.